A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials - Wikidata - wikimedia - TriplyDB

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

http://www.wikidata.org/entity/Q57570787

about

The value of trabectedin in the treatment of soft tissue sarcoma Trabectedin for advanced soft tissue sarcomas: optimizing use Trabectedin in soft tissue sarcomas Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin Treatment of Adult Soft Tissue Sarcomas: An Overview The evolution of systemic therapy in sarcoma.Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline.Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study.Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report.Going further in the knowledge of Yondelis®; what's new in daily clinical practice?Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.Trabectedin clinical cases: use according to indication in diverse clinical scenarios.Trabectedin for the treatment of breast cancer.Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options.Drug-induced hepatotoxicity in cancer patients - implication for treatment.Trabectedin for the treatment of soft tissue sarcomas.Trabectedin for advanced soft tissue sarcomas: a single institution experience.Complete response after rechallenge with trabectedin in a patient with previously responding high-grade undifferentiated sarcoma.Bone sarcomas: from biology to targeted therapies.Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.Neoadjuvant Trabectedin plus Radiotherapy in High-Grade Sarcoma of the Leg: A Case Report

P2860

Q26772855-D5A0B4CE-C438-4785-B97D-4276CD1C86A2 Q26860365-3D874C8B-54FA-4FB3-961A-4AD6C8DF224D Q28085505-C72DBEBF-AC74-41D3-BFC1-0FD9DF213198 Q28087771-86FCAE83-CDE7-4AE9-88D7-998FE32ABC84 Q28088685-72210EE1-6179-445B-A01D-8D833529271C Q33274710-6AC6C595-A0F1-4F53-9E1D-494F7D5D8C17 Q34996149-2F152ECF-B492-4A79-B04D-0646277FBF58 Q35246995-C8E544AD-EE88-4034-99B4-F58F1D778C92 Q35898258-095360B6-4B65-4F38-BF60-B0164A16F1F3 Q35909766-70995EF9-D196-4FCB-BA73-9E7B0CEB05EB Q36099606-5D3BE830-705C-4C1F-A151-70790F1DB5BC Q36530034-94BFD7BB-95F0-4A0A-A681-377B7896C40F Q37350801-A319C2AD-9092-471D-A954-F685775C8100 Q37615789-2B9DCB4E-5F6A-4296-AEC4-114CACF527FA Q38128352-25CD6529-78CF-4326-B5CB-034144D867D4 Q38129954-1E20C2D2-79AB-4895-BB34-1E2C564702A7 Q38136298-AB31817A-2545-4FE7-8858-6BB7E12582CA Q38232372-84D28084-E41E-4FC7-9371-D3328063DBC3 Q38255906-778496D6-3BEA-4A3A-899F-00ECFB479269 Q38515911-1E5992C1-B73F-4738-8856-9210DF09F272 Q38515915-D8A4E7F1-4E5F-415C-BA3C-0D241AAC2005 Q38642314-AE4B910B-833C-445F-994D-4751644E6972 Q38731757-C4CE1E83-0E1B-4C72-89A4-6E8E7C68C60F Q38845891-6F3D2BCF-9C1E-4B71-B5E9-1711F2BF1C63 Q38872192-C6707AE7-2FCC-4DCC-8E4F-A10491049F9F Q39267079-43A9E2DD-A019-42EB-AD0B-6A3DA2204E9B Q41008543-190D5FC6-B860-404C-A15A-EC6138EEE7A3 Q41923624-AB18D734-D49F-48AC-A717-63839EFE0900 Q49605810-FB6B19B5-D235-4B79-9B43-41A4CCEA2C9A Q52603413-4DD2DE44-49EF-4EC4-ADE0-AF8A0226AE6C Q57175456-3D754C81-9F93-49BE-AA8C-F2FF3623702A

P2860

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

http://www.wikidata.org/entity/Q57570787

description

article

@en

im April 2011 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у квітні 2011

@uk

name

A retrospective pooled analysi ...... ed in phase II clinical trials

@en

A retrospective pooled analysi ...... ed in phase II clinical trials

@nl

type

label

A retrospective pooled analysi ...... ed in phase II clinical trials

@en

A retrospective pooled analysi ...... ed in phase II clinical trials

@nl

prefLabel

A retrospective pooled analysi ...... ed in phase II clinical trials

@en

A retrospective pooled analysi ...... ed in phase II clinical trials

@nl

P1433

Q57570787-A6083E82-67C5-44DD-954E-EE6E649A006D

P1476

Q57570787-9F0E89EA-E372-453A-8177-0F5CF9B73FC0

P2093

Q57570787-042E5D2B-B111-4FB1-B98E-14D8F5D44525

Q57570787-4450F5AC-9150-456D-9C57-D7BF97409141

Q57570787-51333E61-C9E3-4357-BDD9-2A27A6E1680C

Q57570787-9193D169-590D-4A45-AE5E-ABE6384DD175

Q57570787-96C0FFC7-0B56-436E-AD28-615E2490C151

Q57570787-A253F3CA-F6B2-42D1-9FE6-D9EAFC5D847A

Q57570787-BD54C305-1372-409F-AE23-1728C01C0D50

Q57570787-DA538E00-477D-4721-BB1A-75368B75A284

P2860

Q57570787-035C2968-8E7D-488A-ABCE-D030CDA290CA

Q57570787-06E6AA57-71F5-40E9-8505-EC8A6A95DAE9

Q57570787-0A2E0804-C0D9-4033-A5E2-4F88F9014B81

Q57570787-0C3C0870-F790-4813-8DCE-5E9295E615D2

Q57570787-0FC25D8F-E61B-4885-B74E-96DA3196F74D

Q57570787-10E9CE80-8A09-4810-95F6-8CB10E84C00D

Q57570787-152729A0-A2B3-4154-8EDA-C1D772291F43

Q57570787-1CF730AB-C462-47D8-B145-6620B226A9CD

Q57570787-3625998F-0CCC-487C-BD5D-40B2181A3B84

Q57570787-47424BE1-4F42-4833-B4D2-6EAECBFA5AEC

P2888

Q57570787-0C468562-C9BD-4A3F-B3E9-46AFA8A3B289

P304

Q57570787-51E71E36-6541-49BF-90C3-A1BD78FBEEDE

P31

Q57570787-85AAABE4-00F4-4126-B48F-F5BB345A1A05

P356

Q57570787-49EA88AB-CEBE-415B-9ED1-862DA122D0E5

P433

Q57570787-A85F5F3F-88A5-4357-9F07-A57C3AFAD70F

P478

Q57570787-4C137CCE-17BF-4132-94A9-C2A2B08650FA

P50

Q57570787-0D9A8036-AA73-4516-8578-404E4A23EA94

Q57570787-FFEDBFC9-B6E8-405F-9B7C-09E630272A09

P577

Q57570787-F0B6E86A-C923-47DD-934B-CB6C4AEF8352

P698

Q57570787-12322DE8-9BF2-41A6-B14C-0CBC5B8DAAA9

P921

Q57570787-4E6787DF-CB70-49B4-8C1D-633B52E78764

P356

S10637-011-9662-0

P1433

Investigational New Drugs

P1476

A retrospective pooled analysi ...... ed in phase II clinical trials

@en

P2093

Alejandro Yovine

http://www.w3.org/2001/XMLSchema#string

Antonio Nieto

http://www.w3.org/2001/XMLSchema#string

Axel Le Cesne

http://www.w3.org/2001/XMLSchema#string

George D. Demetri

http://www.w3.org/2001/XMLSchema#string

Jean-Louis Misset

http://www.w3.org/2001/XMLSchema#string

Juhui James Jiao

http://www.w3.org/2001/XMLSchema#string

Pilar Frontelo

http://www.w3.org/2001/XMLSchema#string

Suzette Delaloge

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

Hepatotoxicity and metabolism of trabectedin: a literature review.

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment.

P2888

s10637-011-9662-0

P304

1193-1202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-011-9662-0

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21484250

http://www.w3.org/2001/XMLSchema#string

P921